Immunotherapy Fits Everyone? Prognostic Markers for Immune-checkpoint-Inhibitor (ICI) in Non-small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Baptista De Almeida, S. [1 ]
Caleca, T. [1 ]
Silva, M. [1 ]
Honorio, M. [1 ]
Chaves, A. [1 ]
机构：
[1] Hosp Prof Doutor Fernando Fonseca, Med Oncol, Amadora, Portugal
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
immune-checkpoint-inhibitor; prognostic markers; non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P57.01
引用
收藏
页码：S1136 / S1136
页数：1
相关论文
共 50 条
  • [31] Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study
    Tian, Tian
    Yu, Min
    Yu, Yang
    Wang, Ke
    Tian, Panwen
    Luo, Ziyue
    Ding, Zhenyu
    Wang, Ye
    Gong, Youling
    Zhu, Jiang
    Zou, Bingwen
    Sio, Terence T.
    Alves, Adelaide
    Liu, Yongmei
    Huang, Meijuan
    Lu, You
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (06) : 1027 - 1037
  • [32] A CASE OF IMMUNE CHECKPOINT INHIBITOR ASSOCIATED MYOCARDITIS IN NON-SMALL CELL LUNG CANCER
    Murphy, Andrew
    Ismail, Ali
    Monzer, Nasser
    Sangoi, Matthew
    Khan, Aarish Husain
    Khazan, Benjamin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 3191 - 3191
  • [33] Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
    Conroy, Michael R.
    Dennehy, Colum
    Forde, Patrick M.
    LUNG CANCER, 2023, 183
  • [34] PATIENT EXPERIENCE OF IMMUNE CHECKPOINT INHIBITOR THERAPY FOR NON-SMALL CELL LUNG CANCER
    Williams, Loretta A.
    Whisenant, Meagan
    Malveaux, Donna
    Singhi, Eric K.
    Altan, Mehmet
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [35] Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer
    Xie, Hao
    Adjei, Alex A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S41 - S43
  • [36] The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
    Watanabe, Hiromi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kudo, Kenichiro
    Minami, Daisuke
    Murakami, Etsuko
    Ochi, Nobuaki
    Ninomiya, Takashi
    Harada, Daijiro
    Yasugi, Masayuki
    Ichihara, Eiki
    Ohashi, Kadoaki
    Fujiwara, Keiichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (08) : 762 - 765
  • [37] MOLECULAR MARKERS IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Heigener, D.
    ANTICANCER RESEARCH, 2011, 31 (05) : 1979 - 1979
  • [38] Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC)
    Desai, Aakash
    Subbiah, Vivek
    Dimou, Anastasios
    Deshane, Jessy
    Goliwas, Kayla
    Ponnazhagan, Selvarangan
    Das, Devika Govind
    Khalil, Maya
    Lo, Ying-Chun
    Lin, Edwin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?
    Gargalionis, Antonios N.
    Papavassiliou, Kostas A.
    Papavassiliou, Athanasios G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
  • [40] TUMOR ENDOTHELIAL MARKERS (TEMS) AS PROGNOSTIC AND PREDICTIVE MARKERS IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Pircher, A.
    Untergasser, G.
    Heidegger, I. M.
    Kern, J.
    Gunsilius, E.
    Fiegl, M.
    Hilbe, W.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
12345